SYBX.OOTC
- Synlogic, Inc.
報價延遲最少15分鐘:2026/02/23 03:02 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.62485 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.26/-6.33
|
|
企業價值
7.32M
|
| 資產負債 |
|
每股賬面淨值
0.88
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
--
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||
|
||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases. |
